CAIV-T

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Influenza

Conditions

Influenza

Trial Timeline

Sep 1, 2000 → May 1, 2002

NCT ID

NCT00192283

About CAIV-T

CAIV-T is a phase 3 stage product being developed by Pfizer for Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT00192283. Target conditions include Influenza.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00192166	Phase 2	Completed	Oct 1, 2002	May 1, 2003	Influenza
NCT00192348	Phase 1	Completed	May 1, 2002	Dec 1, 2002	Healthy
NCT00192400	Phase 3	Completed	Mar 1, 2002	Nov 1, 2002	Healthy
NCT00192426	Phase 3	Completed	Sep 1, 2001	Dec 1, 2001	Influenza
NCT00192231	Phase 3	Completed	Apr 1, 2001	Jun 1, 2001	Influenza
NCT00217230	Phase 3	Completed	Apr 1, 2001	Nov 1, 2001	Influenza
NCT00192192	Phase 3	Completed	Nov 1, 2000	Dec 1, 2000	Influenza
NCT00192270	Phase 2	Completed	Oct 1, 2000	Jan 1, 2001	Healthy
NCT00192283	Phase 3	Completed	Sep 1, 2000	May 1, 2002	Influenza

Competing Products

20 competing products in Influenza

See all competitors

Product	Company	Stage	Hype Score
Influenza vaccine, split inactivated	Comac Medical	Phase 1	25
Vaccine	Comac Medical	Phase 3	69
CT-P27 90 mg/kg + CT-P27 45 mg/kg + Placebo	Celltrion	Phase 2	52
CT-P27 + Placebo	Celltrion	Phase 2	52
CS-8958 + CS-8958 + oseltamivir phosphate	Daiichi Sankyo	Phase 3	77
Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to Oseltamivir	Shionogi	Phase 3	77
Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to Oseltamivir	Shionogi	Phase 3	77
fH1 2 ug + fH1 8 ug + DSP-0546LP 2.5 ug + DSP-0546LP 5 ug + DSP-0546LP 10 ug + Placebo	Sumitomo Pharma	Phase 1	33
Monovalent Influenza Vaccine	AstraZeneca	Approved	85
Monovalent Influenza Vaccine	AstraZeneca	Approved	85
Trivalent Influenza Vaccine	AstraZeneca	Approved	85
AZD4117 + AZD5315	AstraZeneca	Phase 1/2	41
Trivalent Influenza Vaccine	AstraZeneca	Approved	85
FluMist trivalent (2015-2016) + FluMist Quadrivalent (2015-2016) + FluMist Quadrivalent (2017-2018)	AstraZeneca	Approved	85
Trivalent Influenza Virus Vaccine	AstraZeneca	Approved	85
Comparator: Modified Process Vaccine + Comparator: COMVAX™	Merck	Phase 3	77
Molnupiravir + Placebo molnupiravir + Placebo oseltamivir + Oseltamivir + Influenza A Virus	Merck	Phase 1	33
V512 + Comparator: Placebo to V512	Merck	Phase 1	33
Vaxelis + PedvaxHIB	Merck	Approved	85
Seasonal Influenza Vaccine	Novartis	Phase 2	52

Other Products from Pfizer